Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Lin, Chia Hung ^a,b   Lee, Yun Shien ^a,c   Huang, Yu Yao ^a   Hsieh, Sheng Hwu ^a   Chen, Zih Syuan ^b   Tsai, Chi Neu ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c MING CHUAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; MICROSATELLITE DNA;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; DINUCLEOTIDE REPEAT; EXON; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SENSITIVITY INDEX; INTRON; MALE; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARD DEVIATION OF PLASMA GLUCOSE; TREATMENT RESPONSE; DNA SEQUENCE; GENETIC POLYMORPHISM; GENETICS; GLUCOSE TOLERANCE TEST; HOSPITALIZATION; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE TOLERANCE TEST; HOSPITALIZATION; HUMANS; HYPOGLYCEMIA; INFUSIONS, SUBCUTANEOUS; INSULIN; LINKAGE DISEQUILIBRIUM; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; SEQUENCE ANALYSIS, DNA;

EID: 84924347310     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/176949     Document Type: Article

References (29)

1. L. L. Baggio and D. J. Drucker, "Biology of incretins: GLP-1 and GIP, " Gastroenterology, vol. 132, no. 6, pp. 2131-2157, 2007.
2. J. J. Holst, M. Bersani, A. H. Johnsen, H. Kofod, B. Hartmann, and C. Ørskov, "Proglucagon processing in porcine and human pancreas, "The Journal of Biological Chemistry, vol. 269, no. 29, pp. 18827-18833, 1994.
3. D. J. Drucker and M. A. Nauck, "The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, " The Lancet, vol. 368, no. 9548, pp. 1696-1705, 2006.
4. J. M. Egan, A. R. Clocquet, and D. Elahi, "The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes, " The Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3, pp. 1282-1290, 2002.
5. S. L. Anderson, J. M. Trujillo, M. McDermott, and J. J. Saseen, "Determining predictors of response to exenatide in type 2 diabetes, " Journal of the American Pharmacists Association, vol. 52, no. 4, pp. 466-471, 2012.
6. K. Müssig, H. Staiger, F. Machicao et al., "Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion, " Diabetes, vol. 58, no. 7, pp. 1715-1720, 2009.
7. S. A. Schäfer, K. Müssig, H. Staiger et al., "A common genetic variant in WFS1 determines impaired glucagon-like peptide-1- induced insulin secretion, " Diabetologia, vol. 52, no. 6, pp. 1075-1082, 2009.
8. S. A. Schäfer, O. Tschritter, F. Machicao et al., "Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms, " Diabetologia, vol. 50, no. 12, pp. 2443-2450, 2007.
9. G. Smushkin, M. Sathananthan, A. Sathananthan et al., "Diabetes- associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1, " Diabetes, vol. 61, no. 5, pp. 1082-1089, 2012.
10. H.-C. Fehmann, J. Jiang, J. Schweinfurth et al., "Ligandspecificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells, " Zeitschrift fur Gastroenterologie, vol. 32, no. 4, pp. 203-207, 1994.
11. A. Kirkpatrick, J. Heo, R. Abrol, and W. A. Goddard III, "Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 49, pp. 19988-19993, 2012.
12. M. Beinborn, C. I.Worrall, E.W. McBride, and A. S. Kopin, "A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness, " Regulatory Peptides, vol. 130, no. 1-2, pp. 1-6, 2005.
13. J. Woodcock and L. J. Lesko, "Pharmacogenetics-tailoring treatment for the outliers, " The New England Journal of Medicine, vol. 360, no. 8, pp. 811-813, 2009.
14. A. Sathananthan, C. D. Man, F. Micheletto et al., "Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study, " Diabetes Care, vol. 33, no. 9, pp. 2074-2076, 2010.
15. B. W. Bode, "Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections, " Clinical Therapeutics, vol. 29, supplement D, pp. S135-S144, 2007.
16. M. Matsuda and R. A. DeFronzo, "Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp, " Diabetes Care, vol. 22, no. 9, pp. 1462-1470, 1999.
17. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man, " Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
18. B. W. Bode, W. V. Tamborlane, and P. C. Davidson, "Insulin pump therapy in the 21st century: strategies for successful use in adults, adolescents, and children with diabetes, " Postgraduate Medicine, vol. 111, no. 5, pp. 69-77, 2002.
19. C.-H. Lin, C.-H. Huang, J.-S. Tsai et al., "Effects of a novel short-term continuous subcutaneous insulin infusion program evaluated by continuous glucose monitoring on young adult type 1 diabetic patients in Taiwan, " Endocrine Journal, vol. 58, no. 10, pp. 835-840, 2011.
20. Y. Tokuyama, K. Matsui, T. Egashira, O. Nozaki, T. Ishizuka, and A. Kanatsuka, "Five missense mutations in glucagonlike peptide 1 receptor gene in Japanese population, " Diabetes Research and Clinical Practice, vol. 66, no. 1, pp. 63-69, 2004.
21. C.-T. Chang, C.-N. Tsai, C. Y. Tang et al., "Mixed sequence reader: a programfor analyzing DNA sequences with heterozygous base calling, " TheScientificWorld Journal, vol. 2012, Article ID365104, 10 pages, 2012.
22. S. Arnolds, S. Dellweg, J. Clair et al., "Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study, " Diabetes Care, vol. 33, no. 7, pp. 1509-1515, 2010.
23. J. B. Buse, R.M. Bergenstal, L. C. Glass et al., "Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial, " Annals of InternalMedicine, vol. 154, no. 2, pp. 103-112, 2011.
24. S.N.Davis, D. Johns, D.Maggs, H. Xu, J.H.Northrup, and R.G. Brodows, "Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents, " Diabetes Care, vol. 30, no. 11, pp. 2767-2772, 2007.
25. C. Koole, D. Wootten, J. Simms et al., "Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation, "Molecular Pharmacology, vol. 80, no. 3, pp. 486-497, 2011.
26. K. Pilgaard, C. B. Jensen, J. H. Schou et al., "The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men, " Diabetologia, vol. 52, no. 7, pp. 1298-1307, 2009.
27. M. E. Doyle, M. J. Theodorakis, H.W. Holloway, M. Bernier, N. H. Greig, and J. M. Egan, "The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP- 1 receptor and for biological activity, " Regulatory Peptides, vol. 114, no. 2-3, pp. 153-158, 2003.
28. M. E. Doyle, N. H. Greig, H. W. Holloway, J. A. Betkey, M. Bernier, and J. M. Egan, "Insertion of an N-terminal 6- aminohexanoic acid after the 7 amino acid position of glucagonlike peptide-1 produces a long-acting hypoglycemic agent, " Endocrinology, vol. 142, no. 10, pp. 4462-4468, 2001.
29. M. J. Moon, H. Y. Kim, S. Park et al., "Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation, " The Journal of Biological Chemistry, vol. 287, no. 6, pp. 3873-3884, 2012.